https://cdz173inhibitor.com/de....tachment-of-the-pros
This phase 3, randomized, open-label trial involved assigning patients with lenalidomide-refractory multiple myeloma to either cilta-cel or the physician's preferred effective standard treatment. The patients' medical histories all included one to three prior lines of treatment. Survival without disease progression served as the principal measure of effectiveness. Two hundred eight patients were assigned to cilta-cel, and 211 to standard care, compl
Like
Comment
Share
